Literature DB >> 11229827

Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma.

S J Pavey1, G A Hawson, N A Marsh.   

Abstract

Comprehensive studies of fibrinolysis in non-small cell lung carcinoma have been limited, and assignment of patients to high/low prognosis groups based on arbitrary cut-offs utilizing fibrinolytic measurements is unstandardized. This study was performed in 166 patients to examine the effects of cut-off values determined in three ways. Model 1 assigned patients to one of three equal groups (low, medium, high) based on fibrinolytic measurements made at diagnosis, Model 2 divided patients into low/high groups using median values, and Model 3 grouped according to the parameter being above/below normal range. In model 1, raised plasma fibrinogen, D-dimer and soluble fibrin were positively associated with poorer survival. In model 2, tissue plasminogen activator antigen was additionally related to poorer prognosis. Model 3 identified seven parameters as significantly related to survival, two not identified by the other models becoming significant [plasmin-antiplasmin, tissue plasminogen activator inhibitor-1 (PAI-1) antigen]. Using multivariate analysis, plasma fibrinogen level was the most uniformly significant parameter. Relative risk estimates indicated that raised plasma fibrinogen, soluble fibrin and D-dimer were associated with increased risk of death. Use of the normal/above normal cut-off is recommended to provide the maximum number of significant parameters relating to prognosis, and increased plasma D-dimer, PAI-1 antigen and fibrinogen were most closely related to survival/prognosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11229827     DOI: 10.1097/00001721-200101000-00008

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  16 in total

1.  Prognostic role of D-dimer in patients with lung cancer: a meta-analysis.

Authors:  Xuelei Ma; Yanyan Li; Jing Zhang; Jingwen Huang; Lei Liu
Journal:  Tumour Biol       Date:  2013-10-10

2.  Clinical significance of the ratio between the alpha 2 plasmin inhibitor-plasmin complex and the thrombin-antithrombin complex in advanced non-small cell lung cancer.

Authors:  Katsuhiro Masago; Shiro Fujita; Tadashi Mio; Yosuke Togashi; Young Hak Kim; Yukimasa Hatachi; Akiko Fukuhara; Kaoru Irisa; Yuichi Sakamori; Michiaki Mishima
Journal:  Med Oncol       Date:  2010-03-19       Impact factor: 3.064

3.  Do coagulation or fibrinolysis reflect the disease condition in patients with soft tissue sarcoma?

Authors:  Kunihiro Asanuma; Tomoki Nakamura; Takayuki Okamoto; Tomohito Hagi; Kouji Kita; Koichi Nakamura; Yumi Matsuyama; Keisuke Yoshida; Yumiko Asanuma; Akihiro Sudo
Journal:  BMC Cancer       Date:  2022-10-18       Impact factor: 4.638

4.  Advantages of the AMDL-ELISA DR-70 (FDP) assay over carcinoembryonic antigen (CEA) for monitoring colorectal cancer patients.

Authors:  Andrea L Small-Howard; Holden Harris
Journal:  J Immunoassay Immunochem       Date:  2010

5.  Comparison of the serum fibrin-fibrinogen degradation products with cytokeratin 19 fragment as biomarkers in patients with lung cancer.

Authors:  Hee Jin So; Seok-Il Hong; Jin Kyung Lee; Yoon Hwan Chang; Sun Jung Kang; Young Jun Hong
Journal:  Biomed Rep       Date:  2014-07-11

6.  Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.

Authors:  C Ostheimer; C Evers; M Bache; T Reese; D Vordermark
Journal:  Strahlenther Onkol       Date:  2018-01-16       Impact factor: 3.621

7.  STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia.

Authors:  Andrea Bonetto; Tufan Aydogdu; Noelia Kunzevitzky; Denis C Guttridge; Sawsan Khuri; Leonidas G Koniaris; Teresa A Zimmers
Journal:  PLoS One       Date:  2011-07-20       Impact factor: 3.240

8.  High plasma fibrinogen concentration and platelet count unfavorably impact survival in non-small cell lung cancer patients with brain metastases.

Authors:  Jian-Fei Zhu; Ling Cai; Xue-Wen Zhang; Yin-Sheng Wen; Xiao-Dong Su; Tie-Hua Rong; Lan-Jun Zhang
Journal:  Chin J Cancer       Date:  2013-08-19

9.  Endothelial miR-30c suppresses tumor growth via inhibition of TGF-β-induced Serpine1.

Authors:  James V McCann; Lin Xiao; Dae Joong Kim; Omar F Khan; Piotr S Kowalski; Daniel G Anderson; Chad V Pecot; Salma H Azam; Joel S Parker; Yihsuan S Tsai; Alisa S Wolberg; Stephen D Turner; Kohei Tatsumi; Nigel Mackman; Andrew C Dudley
Journal:  J Clin Invest       Date:  2019-03-11       Impact factor: 14.808

10.  Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors.

Authors:  Ge Zhang; Makito Miyake; Adrienne Lawton; Steve Goodison; Charles J Rosser
Journal:  BMC Cancer       Date:  2014-05-03       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.